E-drug: June 2 World Bank Meeting on Generic drugs
-------------------------------------------------------------------------
Workshop on Key Issues in Improving the Accessibility to Drugs in
Developing Countries
Washington DC. June 2, 2003.
Venue: The World Bank, Conference room: I1-200.
Scope and Purpose:
This workshop is part of a World Bank consultation process on The
Role of the Generics and Local Industry in Attaining the MDGs in
Pharmaceuticals and Vaccines.
The workshop objectives are to explore some areas that in the
preparatory meetings were identified as deserving an especial
attention, because it seemed to be limited information on the situation
and problems and no evidence and consensus on how best to
approach them.
The sessions will be video-recorded and made available for public
access at B-SPAN, the World Bank's web casting station on
development issue.
Provisional Program
8.30-9.00
Introductory session:
Mariam Claeson, Lead Public Health Specialist, The World Bank.
MDGs and Pharmaceuticals
Juan Rovira, Senior Health Economist (Pharmaceuticals), The World
Bank James Fitzgerald, Regional Advisor, Pan American Health
Organization / World Health Organization
9.00-11.00
Session 1: Local production in developing countries
Organizer: Warren Kaplan, Boston University
Chair: Ilyse Zable, IFC
The purpose of the session is to identify opportunities for the World
Bank and the IFC to support efficient and sustainable production of
quality drugs.
The session will try to identify our knowledge on pharmaceutical
production in developing countries, as well as the existing gaps. It will
also address the complexities of pharmaceutical production in order to
assess what type of production can be carried out efficiently in
developing countries and try to set a research agenda on local
production issues.
Speaker 1: Warren Kaplan, Boston University. Historical perspective
on local production of pharmaceuticals in developing countries. What
do we really know about local production from a global perspective?
Speaker 2: Bill Haddad, BIOGENERICS. Nature, stages and
characteristics of the process of producing a drug; Practical
approaches in supporting technology transfer for drug production in
developing countries.
Speaker 3: Michael Van Vleck, Phyto-Riker. Practical issues in
creating and maintaining local pharmaceutical production in Ghana.
Speaker 4: Enrique Cavallone ASILFA, Chilean Generics
Manufacturers Association. Technical issues in pharmaceutical
generics production.
11.15-12.30
Session 2: Differential pricing: theory, experiences and proposals
Organizer: Juan Rovira, The World Bank
Chair: F.M. Scherer, Princeton University
The purpose of the session is to review the theoretical framework of
differential, as well as the evidence on its application and effects in
actual cases. The session will also review normative approaches and
proposals for equity pricing as a way to improving access to drugs in
developing countries.
Speaker 1: Carsten Fink, The World Bank. Theory and evidence on
differential pricing
Speaker 2: Juan Rovira, The World Bank. Equity pricing: concept and
proposal
Speaker 3: Patricia M. Danzon, University of Pennsylvania
12.30-1.30 Lunch
1.30-5.00
Session 3: Compensation and Compulsory Licenses: implementing
the Doha Declaration and advancing the UN Millennium Development
Goals
Organizer: Jamie Love, Consumer Project on Technology.
The session will consist of two panels, both addressing the same
question: How does one reconcile the Doha Declaration on TRIPS to
ensure access to medicines for all with the TRIPS obligations on
compensation to patent owners when non-voluntary use of a patent is
authorized?
1.30-3.00 Panel 1
Chair: Rudolf V. Van Puymbroeck, Lead Counsel, The World Bank
Speaker 1: F.M. Scherer, Princeton University. The Economics of
Compulsory Drug Patent Licensing.
Speaker 2: Professor Jerome Reichman, Duke University. Sharing
information from his two recent papers on compulsory licensing for
UNCTAD on US and Canadian experience
Speaker 3: Professor Martin Edelman, George Washington University.
Perspectives of the research based pharmaceutical industry
3.30-5.00 Panel 2
Chair: Yolanda Tayler, Senior procurement Specialist, The World
Bank
Speaker 1: Professor William Jack, Georgetown University and
Professor Jenny Lanjouw, Brookings Institution. A Ramsey Pricing
Model for setting affordable royalties.
Speaker 2: Aidan Hollis, University of Calgary. Setting compensation
for developed and developing countries
Speaker 3: James Love, Consumer Project on Technology.
Affordable royalties in developing countries
Warren Kaplan, Boston University
William Haddad, BIOGENERICS
Michael Van Vleck, Phyto-Riker
Frederic M. Scherer, Princeton University
Carsten Fink, The World Bank
Juan Rovira, The World Bank
Patricia M. Danzon, University of Pennsylvania
Jerome Reichman, Duke University
Marty Edelman, George Washington University
William Jack, Georgetown University
Jenny Lanjouw, Brookings Institution
Aidan Hollis, University of Calgary
James Love, Consumer Project on Technology
Confirmation
Due to space constraints, please confirm attendance to:
Akosua Dakwa
e-mail: adakwa@worldbank.org
phone: +1-202-458.2283.
--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug